Literature meta-analysis about the efficacy of re-challenge with PD-1 and PD-L1 inhibitors in cancer patients - 06/11/20
Méta-analyse de la littérature sur l’efficacité des inhibiteurs du checkpoint immunitaire PD-1/PD-L1 chez les patients cancéreux
, Julie Charles 3, 4, Anne-Claire Toffart 1, Marie-Thérèse Leccia 4, Denis Moro-Sibilot 1, Matteo Giaj Levra 1Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 10 |
| Iconographies | 4 |
| Vidéos | 0 |
| Autres | 0 |
Summary |
Introduction |
Immune checkpoint inhibitor (ICPis) re-challenge could be an attractive therapeutic option considering its good safety profile. However, little data is available regarding anti-PD-1/anti-PD-L1 retreatment. We conducted a meta-analysis focusing on outcomes of solid cancer patients performing this strategy.
Methods |
Fourteen full papers involving 74 patients were included. Individual data about best response or progression-free survival (PFS) upon the first and second course of anti-PD-1/anti-PD-L1 were collected.
Results |
Non-small-cell lung cancer (53%) and melanoma (34%) were the most represented cancers. Higher objective response (46% versus 24%, P=4.10−4) and disease control rates (73% versus 52%, P=7.10−3) were obtained upon the first ICPi course compared to re-challenge. No association between responses obtained with the two ICPis courses was found (P=3.10−1). The PFS upon the first ICPi (PFS1) was longer than after re-challenge (PFSR) (6.6 versus 2.8 months, hazard ratio (HR) 0.57, P=2.10−3). A longer PFSR was obtained in patients with a longer PFS1 (P=6.10−3), in those who discontinued the first ICPi due to toxicity or per protocol (8.8 versus 2.1 months if disease progression occurs, P=2.10−3), and in those not receiving intercalated treatment between the two ICPis (6.6 versus 2.1 months for the treated ones, P=1.10−3).
Discussion |
Anti-PD-1/anti-PD-L1 re-challenge showed interesting clinical activity in selected patients, mainly in those achieving a long-term response upon the first ICPi course, that do not discontinue therapy because of disease progression, or that are able to keep a treatment-free period.
Le texte complet de cet article est disponible en PDF.Keywords : Anti-programmed cell death protein 1, Anti-programmed cell death ligand 1, Immune checkpoint inhibitor, Re-challenge, Solid cancer, Meta-analysis
Plan
Vol 107 - N° 11
P. 1098-1107 - novembre 2020 Retour au numéro
Article précédent
- Sensitivity and polymorphism of Bethesda panel markers in Chinese population
- Yanying Zheng, Jie Chen, Xiang Zhang, Ling Xie, Yifen Zhang, Yi Sun
- Évaluation des interactions médicamenteuses chez des patients traités pour un cancer pulmonaire ou digestif
- Vincent Ghysel, Emmanuelle Tresch, Guillaume Marliot, Romain Nicot, Marc Lambert, Guillaume Carbonnelle, Eric Lartigau, Gautier Lefebvre
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?